No Carolina / NY / Florida
Ph: 561.316.3330

The University of Edinburgh Acknowledges Pelago Patent and Use of ​CETSA ® Process

Summation

  • “The University of Edinburgh wishes to acknowledge the validity of Pelago's CETSA patent (EP 2 699 910 B1) entitled “Methods For Determining Ligand Binding To A Target Protein Using A Thermal Shift Assay” (the “Patent”) and the use of the Cellular Thermal Shift Assay (CETSA®) process described in the Patent in relation to the following works.
  • I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
  • University of Edinburgh acknowledges Pelago Bioscience's CETSA patent and use thereof in selected works in drug discovery research.

The CETSA

University of Edinburgh acknowledges Pelago Bioscience’s CETSA patent and use thereof in selected works in drug discovery research.

In Connection with the CETSA® Platform, the University of Edinburgh States

“The University of Edinburgh wishes to acknowledge the validity of Pelago’s CETSA patent (EP 2 699 910 B1) entitled “Methods For Determining Ligand Binding To A Target Protein Using A Thermal Shift Assay” (the “Patent”) and the use of the Cellular Thermal Shift Assay (CETSA®) process described in the Patent in relation to the following works: Carolin Temps et al., “A novel mode of inhibiting SRC improves drug efficacy and tolerability”, Cancer Research, 20 August 2021, DOI: 10.1158/0008-5472.CAN-21 0613; Chiara Asselborn, Kevin Myant and Alex von Kriegsheim, “Selective vulnerability of colorectal cancer (CRC) organoids to hypoxia-mimetic drug”, presented at the National Cancer Research Institute Cancer Conference in 2018; and; PhD student research to validate binding between integrin linked kinase and three compounds proposed to bind the protein undertaken in around February 2021”

Michael Dabrowski, CEO of Pelago Bioscience Comments on the Agreement

We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.

For more information about Pelago Bioscience and CETSA technology, please visit: www.pelagobio.com

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy